Evaluation of the expression of p53, MDM2, and SUMO-1 in oral lichen planus

Oral Diseases

Volumn 19, Issue 8, 2013, Pages 775-780

  Oliveira Alves, M G ^a   Balducci, I ^a   Rodarte Carvalho, Y ^a   Cabral, L A G ^a   Nunes, F D ^b   Almeida, J D ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Carcinoma; Immunohistochemical; Lichen planus; Proto oncogene proteins c mdm2; Squamous cell; SUMO 1 protein; Tumor suppressor protein p53

Indexed keywords

EOSIN; HEMATOXYLIN; PROTEIN MDM2; PROTEIN P53; SUMO 1 PROTEIN; MDM2 PROTEIN, HUMAN; SUMO1 PROTEIN, HUMAN;

ARTICLE; CHEEK MUCOSA; CONTROLLED STUDY; DYSPLASIA; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; LICHEN PLANUS; MOUTH DISEASE; MOUTH LICHEN PLANUS; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

GENE EXPRESSION REGULATION; GENES, P53; HUMANS; LICHEN PLANUS, ORAL; PROTO-ONCOGENE PROTEINS C-MDM2; SUMO-1 PROTEIN;

EID: 84885933379     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/odi.12068     Document Type: Article

References (37)

1. Anuradha CH, Reddy BV, Nandan SR, Kumar SR (2008). Oral lichen planus. A review. N Y State Dent J 74: 66-68.
2. Barnes L, Eveson JW, Reichart P, Sidransky D (2005). World Health Organization classification of tumours. Pathology & genetics of head and neck tumours, 1th edn. IARC Press: Lyon, p. 181.
3. Berglund L, Björling E, Oksvold P et al (2008). A gene-centric human protein atlas for expression profiles based on antibodies. Mol Cell Proteomics 7: 2019-2027.
4. Buschmann T, Fuchs SY, Lee CG, Pan ZQ, Ronai Z (2000). SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53. Cell 101: 753-762.
5. Coussens LM, Werb Z (2002). Inflammation and cancer. Nature 420: 860-867.
6. Daujat S, Neel H, Piette J (2001). MDM2: life without p53. Trends Genet 17: 459-464.
7. Dong YB, Yang HL, Elliott MJ, McMasters KM (2003). Increased mdm-2 expression in a p53-independent manner blocks UV-induced cell cycle arrest and apoptosis in human osteosarcoma cells. Tumour Biol 24: 130-139.
8. Ebrahimi M, Boldrup L, Coates PJ, Wahlin YB, Bourdon JC, Nylander K (2008). Expression of novel p53 isoforms in oral lichen planus. Oral Oncol 44: 156-161.
9. Eisen D (2002). The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol 46: 207-214.
10. Eisenberg E (2000). Oral lichen planus: a benign lesion. J Oral Maxillofac Surg 58: 1278-1285.
11. Fernández-González F, Vázquez-Álvarez R, Reboiras-López D, Gándara-Vila P, García-García A, Gándara-Rey JM (2010). Histopathological findings in oral lichen planus and their correlation with the clinical manifestations. Med Oral Patol Oral Cir Bucal 15: 225-228.
12. de Freitas MCA, Ramalho LM, Xavier FC, Moreira AL, Reis SR (2008). p53 and MDM2 protein expression in actinic cheilitis. J Appl Oral Sci 16: 414-419.
13. Girod SC, Pfeiffer P, Ries J, Pape HD (1998). Proliferative activity and loss of function of tumour suppressor genes as 'biomarkers' in diagnosis and prognosis of benign and preneoplastic oral lesions and oral squamous cell carcinoma. Br J Oral Maxillofac Surg 36: 252-260.
14. Gonzalez-Moles MA, Gil-Montoya JA, Ruiz-Avila I, Esteban F, Bascones-Martinez A (2008). Differences in the expression of p53 protein in oral lichen planus based on the use of monoclonal antibodies DO7 and pAb 240. Oral Oncol 44: 496-503.
15. Ingafou M, Leao JC, Porter SR, Scully C (2006). Oral lichen planus: a retrospective study of 690 British patients. Oral Dis 12: 463-468.
16. Ismail SB, Kumar SKS, Zain RB (2007). Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation. J Oral Sci 49: 89-106.
17. Katayama A, Ogino T, Bandoh N et al (2007). Overexpression of small ubiquitin-related modifier-1 and sumoylated Mdm2 in oral squamous cell carcinoma: possible involvement in tumor proliferation and prognosis. Int J Oncol 31: 517-524.
18. Kim KI, Baek SH (2006). SUMOylation code in cancer development and metastasis. Mol Cells 22: 247-253.
19. Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K (2005). Current controversies in oral lichen planus: report of an international consensus meeting. Part 2. Clinical management and malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100: 164-178.
20. Mantovani A, Allavena P, Sica A, Balkwill F (2008). Cancer-related inflammation. Nature 454: 436-444.
21. Meek DW, Knippschild U (2003). Posttranslational modification of MDM2. Mol Cancer Res 1: 1017-1026.
22. van der Meij EH, van der Waal I (2003). Lack of clinicopathologic correlation in the diagnosis of oral lichen planus based on the presently available diagnostic criteria and suggestions for modifications. J Oral Pathol Med 32: 507-512.
23. van der Meij EH, Schepman KP, van der Waal I (2003). The possible premalignant character of oral lichen planus and oral lichenoid lesions: a prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 96: 164-171.
24. Melchior F, Hengst L (2000). Mdm2-SUMO1: is bigger better? Nat Cell Biol 2: E161-E163.
25. Mignogna MD, Fedele S, Lo Russo L, Lo Muzio L, Bucci E (2004). Immune activation and chronic inflammation as the cause of malignancy in oral lichen planus: is there any evidence? Oral Oncol 40: 120-130.
26. Momand J, Wu HH, Dasgupta G (2000). MDM2-master regulator of the p53 tumor suppressor protein. Gene 242: 15-29.
27. Nakagawa K, Yamamura K, Maeda S, Ichihashi M (1994). Bcl-2 expression in epidermal keratinocytic diseases. Cancer 74: 1720-1724.
28. Oliveira Alves MG, Almeida JD, Balducci I, Guimarães Cabral LA (2010). Oral lichen planus: a retrospective study of 110 Brazilian patients. BMC Res Notes 3: 157-160.
29. Qian BZ, Pollard JW (2010). Macrophage diversity enhances tumor progression and metastasis. Cell 141: 39-51.
30. Safadi RA, Al Jaber SZ, Hammad HM, Hamasha AA (2010). Oral lichen planus shows higher expressions of tumor suppressor gene products of p53 and p21 compared to oral mucositis. An immunohistochemical study. Arch Oral Biol 55: 454-461.
31. Scully C, el-Kom M (1985). Lichen planus: review and update on pathogenesis. J Oral Pathol 14: 431-458.
32. Sousa FACG, Paradella TC, Carvalho YR, Rosa LEB (2009). Comparative analysis of the expression of proliferating cell nuclear antigen, p53, bax, and bcl-2 in oral lichen planus and oral squamous cell carcinoma. Ann Diagn Pathol 13: 308-312.
33. Souza PE, Mesquita RA, Gomez RS (2000). Evaluation of p53, PCNA, Ki-67, MDM2 and AgNOR in oral peripheral and central giant cell lesions. Oral Dis 6: 35-39.
34. Stoll C, Baretton G, Ahrens C, Löhrs U (2000). Prognostic significance of apoptosis and associated factors in oral squamous cell carcinoma. Virchows Arch 436: 102-108.
35. Tanda N, Mori S, Saito K, Ikawa K, Sakamoto S (2000). Expression of apoptotic signaling proteins in leukoplakia and oral lichen planus: quantitative and topographical studies. J Oral Pathol Med 29: 385-393.
36. van der Waal I (2009). Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol 45: 317-323.
37. Xue JL, Fan MW, Wang SZ, Chen XM, Li Y, Wang L (2005). A clinical study of 674 patients with oral lichen planus in China. J Oral Pathol Med 34: 467-472.